Barclays PLC Purchases 72,192 Shares of Innoviva, Inc. (NASDAQ:INVA)

Barclays PLC boosted its holdings in shares of Innoviva, Inc. (NASDAQ:INVA) by 254.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 100,594 shares of the biotechnology company’s stock after acquiring an additional 72,192 shares during the period. Barclays PLC owned approximately 0.16% of Innoviva worth $1,942,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in INVA. MML Investors Services LLC lifted its position in Innoviva by 19.4% in the 3rd quarter. MML Investors Services LLC now owns 18,375 shares of the biotechnology company’s stock valued at $355,000 after acquiring an additional 2,985 shares in the last quarter. Jane Street Group LLC lifted its holdings in shares of Innoviva by 46.4% in the third quarter. Jane Street Group LLC now owns 136,361 shares of the biotechnology company’s stock valued at $2,633,000 after purchasing an additional 43,218 shares in the last quarter. Systematic Financial Management LP boosted its position in shares of Innoviva by 4.7% during the third quarter. Systematic Financial Management LP now owns 1,979,073 shares of the biotechnology company’s stock worth $38,216,000 after buying an additional 89,633 shares during the period. Walleye Capital LLC bought a new position in shares of Innoviva during the third quarter worth about $214,000. Finally, Martingale Asset Management L P raised its position in Innoviva by 0.7% in the 3rd quarter. Martingale Asset Management L P now owns 77,842 shares of the biotechnology company’s stock valued at $1,503,000 after buying an additional 550 shares during the last quarter. 99.12% of the stock is owned by institutional investors and hedge funds.

Innoviva Price Performance

NASDAQ INVA opened at $17.65 on Friday. The firm’s 50 day moving average is $19.18 and its 200-day moving average is $18.55. The company has a quick ratio of 1.64, a current ratio of 1.79 and a debt-to-equity ratio of 0.38. The company has a market capitalization of $1.10 billion, a PE ratio of 25.58 and a beta of 0.53. Innoviva, Inc. has a 12-month low of $14.32 and a 12-month high of $21.28.

Innoviva (NASDAQ:INVA) last announced its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.27 by ($0.25). The company had revenue of $89.51 million during the quarter. Innoviva had a net margin of 18.31% and a return on equity of 20.84%. Equities research analysts anticipate that Innoviva, Inc. will post 0.33 earnings per share for the current fiscal year.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.